Alterola sells Phytanix to Protagenic, plans to deregister; directors resign

ALTEROLA BIOTECH INC.

Alterola and EMC2 sold 100% of Phytanix to Protagenic for Protagenic common and preferred stock; combined ownership: 35% existing Protagenic, 65% Alterola/EMC2.
Alterola shareholders will be offered the option to swap ABTI shares for Protagenic shares; shareholder vote required by September 1, 2025.
Alterola intends to terminate SEC registration and become a privately held company to reduce costs.
Executive Chairman Tim Rogers, CEO David Hitchcock, CFO Nathan Thompson, and three independent directors resigned; Dominic Schiller and Colin Stott remain.

item 1.01item 2.01item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.